Formulation and evaluation of controlled release ocusert of gatifloxacin and prednisolone

1. Zaki I, Fitzgerald P, Hardy J, Wilson C. A comparison of the effect of viscosity on the precorneal residence of solutions in rabbit and man. Journal of pharmacy and pharmacology. 1986;38(6):463-6.10.1111/j.2042-7158.1986.tb04611.x2873224Search in Google Scholar

2. Lee VH, Robinson, R J. Topical ocular drug delivery: recent developments and future challenges. Journal of ocular pharmacology and therapeutics. 1986;2(1):67-108.10.1089/jop.1986.2.673332284Search in Google Scholar

3. Karthikeyan D, Bhowmick M, Pandey VP, Nandhakumar J, Sengottuvelu S, Sonkar S, et al. The concept of ocular inserts as drug delivery systems: An overview. Asian Journal of Pharmaceutics. 2014;2(4):192-200.10.4103/0973-8398.45031Search in Google Scholar

4. Friedrich SW, Saville BA, Cheng Y-L, Rootman DS. Pharmacokinetic differences between ocular inserts and eyedrops. Journal of ocular pharmacology and therapeutics. 1996;12(1):5-18.10.1089/jop.1996.12.58925396Search in Google Scholar

5. Schoenwald R. Ocular pharmacokinetics/pharmacodynamics. Drug and the pharmaceutical sciences. 1993;58:83-110.Search in Google Scholar

6. Kumar KS, Bhowmik D, Harish G, Duraivel SJ. Ocular inserts: A novel controlled drug delivery system. The Pharma Innovation Journal. 2013;1(12, Part A):1-16.Search in Google Scholar

7. Cervantes LJ, Mah FS. Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis. Clinical ophthalmology (Auckland, NZ). 2011;5:495-502.Search in Google Scholar

8. Mohd Abul K, Aws A, Ibrahim AA, Anil KM, Yasmin S. Delivery of gatifloxacin using microemulsion as vehicle: formulation, evaluation, transcorneal permeation and aqueous humor drug determination. Drug Delivery. 2014;23(3):886-97.Search in Google Scholar

9. Pawar P, Katara R, Mishra S, Majumdar DK. Topical ocular delivery of fluoroquinolones. Expert opinion on drug delivery. 2013;10(5):691-711.10.1517/17425247.2013.77297723419018Search in Google Scholar

10. Perry CM, Balfour JAB, Lamb HM. Gatifloxacin. Drugs. 1999;58(4):683-96.10.2165/00003495-199958040-0001010551438Search in Google Scholar

11. Indian Pharmacopoeia. Government of India, ministry of health and family welfare. Delhi: Controller of Publications. 2010:1402,951.Search in Google Scholar

12. Laurell CG, Zetterström C. Effects of dexamethasone, diclofenac, or placebo on the inflammatory response after cataract surgery. Br J Ophthalmol. 2002;86(12):1380-4.10.1136/bjo.86.12.1380177143912446370Search in Google Scholar

13. Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol. 2006;148(3):245-54.10.1038/sj.bjp.0706736175155916604091Search in Google Scholar

14. Ilyas H, Slonim CB, Braswell GR, Favetta JR, Schulman M. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye contact lens. 2004;30(1):10-3.10.1097/01.ICL.0000092071.82938.4614722462Search in Google Scholar

15. Campos M, Muccioli C, Malta JB, Gerade RA, A LAS, Belfort R. Efficacy and tolerability of a combined gatifloxacin plus prednisolone formulation for topical prophylaxis after LASIK. Clinical ophthalmology (Auckland, NZ). 2011;5:209-14.Search in Google Scholar

16. Awan MA, Agarwal PK, Watson DG, McGhee CN, Dutton GN. Penetration of topical and subconjunctival corticosteroids into human aqueous humour and its therapeutic significance. Br J Ophthalmol. 2009;93(6):708-13.10.1136/bjo.2008.15490619293163Search in Google Scholar

17. Kiningham KK. Prednisolone. xPharm: The Comprehensive Pharmacology Reference. 2007:1-6.10.1016/B978-008055232-3.62454-7Search in Google Scholar

18. Cunha PA, Shinzato FA, Tecchio GT, Weber SL, Brasil A, Avakian A. Efficacy and tolerability of a gatifloxacin/prednisolone acetate fixed combination for topical prophylaxis and control of inflammation in phacoemulsification: a 20-day-double-blind comparison to its individual components. Clinics (Sao Paulo, Brazil). 2013;68(6):834-9.10.6061/clinics/2013(06)18Search in Google Scholar

19. Ayaki M, Taguchi Y, Soda M, Yaguchi S, Iwasawa A, Koide R. Cytotoxicity of topical medications used for infection and inflammation control after cataract surgery in cultured corneal endothelial cells. Biocontrol science. 2010;15(3):97-102.10.4265/bio.15.9720938094Search in Google Scholar

20. Ayaki M, Yaguchi S, Iwasawa A, Koide R. Cytotoxicity of ophthalmic solutions with and without preservatives to human corneal endothelial cells, epithelial cells and conjunctival epithelial cells. Clinical & experimental ophthalmology. 2008;36(6):553-9.10.1111/j.1442-9071.2008.01803.x18954319Search in Google Scholar

21. Banu S, Farheen SA. Ocular Drug Delivery System: A Novel Approach. Asian Journal of Research in Pharmaceutical Science. 2019;9(2):97-106.10.5958/2231-5659.2019.00015.8Search in Google Scholar

22. Kumari A, Sharma P, Garg V, Garg G. Ocular inserts - Advancement in therapy of eye diseases. J Adv Pharm Technol Res. 2010;1(3):291-6.10.4103/0110-5558.72419325540722247860Search in Google Scholar

23. Rajesh A, Poonam D, Sangeeta A. Ocular drug delivery system: ocular insert. International Journal of Universal Pharmacy and Bio Sciences. 2012;1(2):30-8.Search in Google Scholar

24. Kumari A, Sharma PK, Garg VK, Garg G. Ocular inserts - Advancement in therapy of eye diseases. J Adv Pharm Technol Res. 2010;1(3):291-6.10.4103/0110-5558.72419Search in Google Scholar

25. Ghosh S, Barik B. Formulation and in vitro evaluation of once daily sustained release formulation of aceclofenac. Tropical journal of pharmaceutical research. 2010;9(3):265-73.10.4314/tjpr.v9i3.56288Search in Google Scholar

26. Freire F, Aragão C, de Lima e Moura T, Raffin F. Compatibility study between chlorpropamide and excipients in their physical mixtures. Journal of thermal analysis calorimetry. 2009;97(1):355-7.10.1007/s10973-009-0258-2Search in Google Scholar

27. Renu C, Swati B. Drug–excipient compatibility screening—Role of thermoanalytical and spectroscopic techniques. Journal of Pharmaceutical and Biomedical Analysis. 2014;87:82-97.10.1016/j.jpba.2013.06.01623845418Search in Google Scholar

28. Oliveira G, Ferraz H, Matos J. Thermoanalytical study of glibenclamide and excipients. Journal of thermal analysis calorimetry. 2005;79(2):267-70.10.1007/s10973-005-0047-5Search in Google Scholar

29. Ibrahim HK, El-Leithy IS, Makky AA. Mucoadhesive Nanoparticles as Carrier Systems for Prolonged Ocular Delivery of Gatifloxacin/Prednisolone Bitherapy. Molecular Pharmaceutics. 2010;7(2):576-85.10.1021/mp900279c20163167Search in Google Scholar

30. Tanwar Y, Patel D, Sisodia S. In vitro and in vivo evaluation of ocular inserts of ofloxacin. DARU. 2007:139-45.Search in Google Scholar

31. Karthikeyan D, Bhowmick M, Pandey V, Sengottuvelu S, Sonkar S, Gupta N, et al. Design and evaluation of ofloxacin extended release ocular inserts for once a day therapy. Res J Pharm Tech. 2008;1(4):460-8.Search in Google Scholar

32. Kalyanwat R, Shrivastava B, Pathak K. Preparation and Evaluation of bioadhesive ocular inserts of aceclofenac. International Journal of Pharmaceutical Sciences Review and Research. 2016;41:207-13.Search in Google Scholar

33. Saroot R, Gilhotra RM. Design and characterization of bioadhesive ophthalmic films of flurbiprofen. Thai Journal of Pharmaceutical Science. 2011;35:29-39.Search in Google Scholar

34. Pawar S, Pawar R, Gadhve M. Controlled release in situ forming gatifloxacine HCl for ophthalmic drug delivery. Int Res J of Phar. 2012;3:86-9.Search in Google Scholar

35. Patel UL, Chotai NP, Nagda CD. Design and evaluation of ocular drug delivery system for controlled delivery of gatifloxacin sesquehydrate: In vitro and in vivo evaluation. Pharmaceutical development technology. 2012;17(1):15-22.10.3109/10837450.2010.50217820649410Search in Google Scholar

36. Mathurm M, Gilhotra RM. Glycerogelatin-based ocular inserts of aceclofenac: physicochemical, drug release studies and efficacy against prostaglandin E2-induced ocular inflammation. Drug delivery. 2011;18(1):54-64.10.3109/10717544.2010.50936620718601Search in Google Scholar

37. Charoo NA, Kohli K, Ali A, Anwer A. Ophthalmic delivery of ciprofloxacin hydrochloride from different polymer formulations: in vitro and in vivo studies. Drug development industrial pharmacy. 2003;29(2):215-21.10.1081/DDC-120016729Search in Google Scholar

38. Chandran S, Roy A, Saha RN. Effect of pH and formulation variables on in vitro transcorneal permeability of flurbiprofen: a technical note. Aaps Pharmscitech. 2008;9(3):1031-7.10.1208/s12249-008-9139-4297702518792792Search in Google Scholar

39. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217-23.Search in Google Scholar

40. Indian Pharmacopoeia. Government of India, ministry of health and family welfare. Delhi: Controller of Publications. 1996;2(35):448-89, A-147.Search in Google Scholar

41. ICH harmonized tripartite guideline. Stability testing of new drug substances andproducts Q1A (R2).1-18.Search in Google Scholar